Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526413 | 1.00 | PTGER1 (0.31) | PTGER1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7525881 | 0.97 | BCHE (0.32) | — | |
| SCHEMBL7525880 | 0.97 | BCHE (0.32) | — | |
| SCHEMBL1389062 | 0.96 | BCHE (0.33) | — | |
| SCHEMBL1717405 | 0.96 | BCHE (0.33) | — | |
| SCHEMBL12632563 | 0.96 | BCHE (0.33) | — | |
| SCHEMBL7514355 | 0.96 | BCHE (0.33) | — | |
| SCHEMBL1388984 | 0.96 | BCHE (0.33) | — | |
| Hydrochloric Acid SCHEMBL7513256 | 0.95 | BCHE (0.33) | — | |
| Hydrochloric Acid SCHEMBL7513262 | 0.95 | BCHE (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975592-B1 | BENZYLOXY PRODIGIOSINE COMPOUNDS | PHARMACIA & UPJOHN SPA (IT) | 2002-06-05 | — | — | EP | claimed |
| US-20020049248-A1 | Alone or in combination for treatment of adult-T-cell leukemia- lymphoma | PHARMACIA & UPJOHN, SPA (IT) | 2002-04-25 | — | — | US | claimed |
| US-6369096-B1 | IMMUNOMODULATING AGENT, IMMUNOSUPPRESSANT | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-04-09 | — | — | US | claimed |
| EP-0975592-B1 | BENZYLOXY PRODIGIOSINE COMPOUNDS | PHARMACIA & UPJOHN SPA (IT) | 2002-06-05 | — | — | EP | disclosed |
| US-20020049248-A1 | Alone or in combination for treatment of adult-T-cell leukemia- lymphoma | PHARMACIA & UPJOHN, SPA (IT) | 2002-04-25 | — | — | US | disclosed |
| US-6369096-B1 | IMMUNOMODULATING AGENT, IMMUNOSUPPRESSANT | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049248-A1 | Alone or in combination for treatment of adult-T-cell leukemia- lymphoma | MALT1, BCL6, CD4 | PTGER1 1331/4885PDE4A 4277/4885PDE4B 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.